AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01671293 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care from health centers consisting of medical indication of physical activity and healthy eating recommendations, as well as referral to Dietitian if appropriate, an invitation to participate in educational activities at health centers and periodic inspection appointments
Study NCT00385944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Prasugrel 10-mg tablet taken orally as a daily maintenance dose for a 14-day treatment period.
Study NCT00385944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel two 75-mg tablets taken orally as a daily maintenance dose for a 14-day treatment period.
Study NCT03082183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: once daily
Study NCT03082183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: once daily
Study NCT02332278 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late feeding
Description: Fluid diet 12 hours after cesarean section
Study NCT01087398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen)
Description: For sibling full match:~* Busulfan 16 mg/kg >5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~* Busulfan 16 mg/kg >5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* ATG rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~* Busulfan 16 mg/kg >5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Fludarabine 160 mg/m\^2
Study NCT01087398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:~1. Sibling full match~2. Other related full match~3. Sibling or other related with 1 mismatch antigen~4. Cord Blood~5. Haploidentical
Study NCT01087398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin, Methotrexate (GVHD prophylaxis)
Description: * Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in PBSCT and +11 in BMT or UCBT) then 9 mg/kg/day po~* 10 mg/m\^2 iv day +1 then 6 mg/m\^ iv day +3 and +6 (Not for UCBT)
Study NCT02466360 — intervention group
Intervention type: BEHAVIORAL
Intervention: Back Belief questionnaire
Study NCT02466360 — intervention group
Intervention type: BEHAVIORAL
Intervention: QUEBEC scale
Study NCT02466360 — intervention group
Intervention type: BEHAVIORAL
Intervention: Fear Avoidance beliefs questionnaire
Study NCT02466360 — intervention group
Intervention type: BEHAVIORAL
Intervention: Visual analog scale
Study NCT02466360 — intervention group
Intervention type: BEHAVIORAL
Intervention: individual interviews
Study NCT02466360 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus groups
Study NCT02664168 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel Ag Surgical Dressing
Study NCT02664168 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single-Use Negative Pressure Wound Therapy (PICO)
Study NCT03858114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mild-to-moderate physical activity
Description: According to ACSM guidelines, mild-to-moderate Physical Activity (PA) will be established as ≤ 60% of the Heart Rate Reserve (HRR). Baseline HR will be registered for all participants for three days, and the mean data will be utilized. PA intervention will consist of three phases:~1. warm up (10 minutes), up to 40% of HRR, with slow, dynamic movements and stretching for principal muscular groups;~2. Active phase (45 minutes), from >40% to 60% HRR, with static and dynamic exercises for postural control and spine mobility, and balance exercises, with activation of core muscles;~3. cool down (10 minutes), \< 40% of HRR, with cardiorespiratory cool-down exercises followed by relaxation, and post-stretch exercises to return muscles to a pre-exercises length.
Study NCT03858114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cultural group program
Description: A cultural group program with 12-weeks thematic meetings on places of historical and artistic interest in the city of Cagliari, Sardinia, with one visit/week to the same sites. The participants will be accompanied by expert tour guides to museums, monuments, city parks and archeological sites.
Study NCT00983021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Single, simultaneous dose of NN9068, injected s.c. (under the skin)
Study NCT00983021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Single, simultaneous dose of NN1250, injected s.c. (under the skin)
Study NCT00983021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Single, simultaneous dose of NN2211, injected s.c. (under the skin)
Study NCT00983021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single, simultaneous dose of NN2211, injected s.c. (under the skin)
Study NCT00983021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single, simultaneous dose of placebo, injected s.c. (under the skin)
Study NCT00983021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Single, simultaneous dose of placebo, injected s.c. (under the skin)
Study NCT01708681 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lean seafood
Study NCT01708681 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lean seafood
Study NCT04845009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive muscle relaxation
Description: progressive muscle relaxation
Study NCT04845009 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual care
Study NCT01708681 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meat, egg, milk
Study NCT01708681 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meat, egg, milk
Study NCT02258750 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polydextrose
Description: High fibre polydextrose enriched tomato soup (matched for sensory and nutritional characteristics to control) and eaten one hour before an ad-libitum lunch on study days. A 410g pre-packaged portion will be provided which contains 6% polydextrose compared to control.
Study NCT02258750 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Tomato soup (matched for sensory and nutritional characteristics to control) served in a 410g portion and eaten one hour before an ad-libitum lunch on study days.
Study NCT01237457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATATE
Description: Patients will receive 200mCi dose of 177Lu Dotatate
Study NCT05455918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIP treatment (paclitaxel/ifosfamide/cisplatin)
Description: Paclitaxel 240mg/m2/day D1 (total 240mg/m2) Ifosfamide 1.5g/m2/day D2\~5 (total 6g/m2) Cisplatin 25mg/m2/day D2\~5 (total 100mg/m2)
Study NCT00290771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib tablets
Description: Imatinib was supplied as 100 and 400 mg tablets by Novartis.
Study NCT00290771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea capsules
Description: Hydroxyurea was supplied locally as 500 mg capsules.
Study NCT02183480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin, low dose
Study NCT02183480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin, medium dose
Study NCT02183480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin, high dose
Study NCT03311139 — intervention group
Intervention type: DRUG
Intervention: Antithrombotic agents
Description: Antiplatelets and anticoagulants purchased 4 months before and within 7 days after the index date
Study NCT02450448 — intervention group
Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.
Study NCT02450448 — intervention group
Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
Study NCT02671903 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker: AV optimised, His pacing.
Description: Direct His bundle pacing: a Medtronic Select Secure 3830 pacing lead will be positioned at the His bundle. If selective direct His bundle pacing cannot be achieved then non-selective His bundle pacing will be accepted. AV delay optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems, Netherlands).
Study NCT04319029 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmaceutical care plan
Description: The design of the intervention was based on a stepwise approach to address the following point in each participant: set priorities for patient care, assessment of patient's educational needs, and development of a comprehensive and achievable pharmaceutical care plan.~The participants will be educated about their illness and informed about the proper use of their medication in a structured manner (it involved the following items: dyslipidemia as a disease, complications, who therapy reduces its risk and complications, goal of therapy). Behavioral modifications will involve the following: physical exercise, diet, smoking cessation. Patients will obtain this information verbally and provided in a written manner through a brochure that design for this study.
Study NCT01025076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StomaphyX
Description: StomaphyX with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) is a transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
Study NCT04033887 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 13 Rapid Diagnostic Tests and reference tests
Description: Rapid diagnostic tests:~1. HCV antibody test (under development); bioLytical Laboratories~2. DPP® HCV (under development); Chembio Diagnostic Systems~3. HCV-Ab Rapid Test; Beijing Wantai Biological Pharmacy Enterprise~4. Rapid Anti-HCV Test; InTec~5. First Response HCV Card Test; Premire Medical Corporation~6. Signal HCV Ver 3.0; Arkray healthcare~7. TRI DOT HCV; J. Mitra \& Co~8. Triplex HIV, HCV, HBsAg; Biosynex SA~9. Standard Q HCV Ab; SD Biosensor~10. HCV Hepatitis Virus Antibody Test; Artron Laboratories~11. SD Bioline HCV; Abbott Diagnostics~12. OraQuick HCV; OraSure~13. Care Start HCV Rapid Test (under development); Access Bio~Reference tests:~Enzyme Immunoassays (EIAs): Murex Anti-HCV EIA version 4.0; Fujirebio Innotest HCV Ab IV~Line Immunoassay (LIA): MP Diagnostics HCV blot 3.0
Study NCT01331382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trans- resveratrol
Description: All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
Study NCT01331382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Trans- resveratrol
Description: All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
Study NCT01331382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (silica)
Description: All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
Study NCT01331382 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (silica)
Description: All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
Study NCT03458273 — intervention group
Intervention type: PROCEDURE
Intervention: Zero fluoroscopy ablation
Description: Catheter ablation for the treatment of atrial and ventricular arrhythmia - no fluoroscopy guidance
Study NCT03458273 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional ablation without 3D
Description: Catheter ablation for the treatment of atrial and ventricular arrhythmia - fluoroscopy guidance only. 3D system (Every Ensite/Carto) is not allowed
Study NCT03458273 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional ablation with 3D
Description: Catheter ablation for the treatment of atrial and ventricular arrhythmia - fluoroscopy guidance + 3D system support (Ensite/Carto)
Study NCT03147014 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Maternal hyperoxygenation
Description: approximately 10-15 minutes of maternal hyperoxygenation
Study NCT01804296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
Study NCT04325581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 6 MG/ML
Description: Liraglutide in incremental dose upto maximum of 1.8 mg per day SC daily
Study NCT04325581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Normal Saline SC daily
Study NCT04498013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclodynon
Description: Cyclodynon 1 tablet a day during 6 menthes period.
Study NCT04498013 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyl modification
Description: Measures to normalize the hygiene of work and rest. A diet aimed at achieving an optimal body mass index. Teaching relaxation techniques to increase resistance to chronic stress.
Study NCT04498013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyl modification
Description: Measures to normalize the hygiene of work and rest. A diet aimed at achieving an optimal body mass index. Teaching relaxation techniques to increase resistance to chronic stress.
Study NCT03208855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: 8 week 1-hour sessions of group CBT-I with each group including 3-4 men.
Study NCT04193345 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Documentation of Maternal blood loss and neonatal outcome
Description: Comparing and monitoring the maternal blood loss and neonatal effect of delayed umbilical cord clamping and early umbilical cord clamping after delivery of the baby durin cesarean delivery in severe preeclampsia
Study NCT04670458 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT01529983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: The treated sites are both lower eyelids and lateral orbits. Each side will be randomized to receive 1550nm-fractionated laser treatment on one side and the contralateral side will receive micro-focused ultrasound treatment every 6-8 weeks for a total of 2 treatments
Study NCT01529983 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser treatment
Description: The treated sites are both lower eyelids and lateral orbits. Each side will be randomized to receive 1550nm-fractionated laser treatment on one side and the contralateral side will receive micro-focused ultrasound treatment every 6-8 weeks for a total of 2 treatments
Study NCT02141698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets
Study NCT02141698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-438 Placebo
Description: TAK-438 placebo-matching tablets
Study NCT02141698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole tablets
Study NCT01453751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Harvesting and Implantation of Adipose-Derived Stromal Vascular Fraction (AD-SVF)
Description: ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells.
Study NCT06058247 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active nutritional supplementation
Description: The participants in active nutritional supplementation arm received consultation from the nutritional support team (NST) upon ICU admission, and nutritional supplementation was initiated on the same day.~NST is a multidisciplinary support team comprised of physicians, nurses, dietitians, and pharmacists, which assesses the nutritional status of patients, and provides recommendations for nutritional therapy. Targets in the participants in active nutritional supplementation arm were protein supplementation at over 1.5 g/kg/day, calorie provision at over 20 kcal/kg/day, and energy adequacy of at least 80%. Energy target was estimated by multiplying the resting energy expenditure using the Harris and Benedict equation by an activity factor of 1.3 and a stress factor of 1.1. Actual body weight was used as the body weight for patients with a percent of ideal body weight (PIBW) of less than 120%, while adjusted body weight was used for patients with a PIBW greater than or equal to 120%.
Study NCT06058247 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conventional nutritional supplementation
Description: The participants in conventional nutritional supplementation arm received conservative nutritional management without specific protein or caloric targets.
Study NCT04136327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 film-coated tablets
Description: single oral dose of GLPG1972
Study NCT04136327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GLPG1972 solution for infusion
Description: a 15-minute IV infusion \[14C\]-GLPG1972
Study NCT04136327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GLPG1972 oral solution
Description: single oral dose of \[14C\]-GLPG1972
Study NCT01292356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Study NCT03350958 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alginate Bread
Description: 100g Alginate Bread, toasted with 20g of butter.
Study NCT03350958 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alginate Bread
Description: 100g Alginate Bread, toasted with 20g of butter.
Study NCT00609492 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)
Description: Single dose, intramuscular injection
Study NCT00609492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)
Description: Single dose, intramuscular injection
Study NCT00609492 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™-IPV/Hib
Description: Single dose, intramuscular injection
Study NCT00609492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™-IPV/Hib
Description: Single dose, intramuscular injection
Study NCT01713972 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dabrafenib
Description: Given PO
Study NCT01713972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib
Description: Given PO
Study NCT01713972 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pazopanib hydrochloride
Description: Given PO
Study NCT01713972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Given PO
Study NCT01713972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Correlative studies
Description: Pharmacokinetic studies:~Blood draw for various time points:~Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12~* Pharmacogenomic studies: Blood draw on Cycle 1 Day 1~* Tumor genotyping: Archival tumor blocks or unstained slides~* BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression
Study NCT01713972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative studies
Description: Pharmacokinetic studies:~Blood draw for various time points:~Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12~* Pharmacogenomic studies: Blood draw on Cycle 1 Day 1~* Tumor genotyping: Archival tumor blocks or unstained slides~* BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression